RBC Capital Downgrades Adverum Biotechnologies (ADVM) to Sector Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
After-Hours Stock Movers 04/28: (GRTX) (AZPN) (CAKE) Higher; (ADVM) (CMCO) (HOLX) Lower (more...)
April 28, 2021 5:45 PM EDTToday's After-Hours Movers:
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) 54% LOWER; announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME). This event occurred 30 weeks after randomization in one patient treated with a single intravitreal injection of the high dose (6 x 10^11 vg/eye) of ADVM-022 who has developed hypotony, with panuveitis and loss of vision in the treated eye.
Galera Therapeutics, Inc. (Nasdaq:... More
Adverum Biotechnologies (ADVM) announced Suspected Unexpected Serious Adverse Reaction of hypotony in its INFINITY clinical trial evaluating ADVM-022
April 28, 2021 4:04 PM EDTAdverum Biotechnologies, Inc. (Nasdaq: ADVM) announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME). This event occurred 30 weeks after randomization in one patient treated with a single intravitreal injection of the high dose (6 x 10^11 vg/eye) of ADVM-022 who has developed hypotony, with panuveitis and loss of vision in the treated eye.
In the interests of patient safety, Adverum has decided to immediately unmask the INFINITY Phase 2... More
Adverum Biotechnologies (ADVM) Halted, News Pending
April 28, 2021 4:02 PM EDTAdverum Biotechnologies (NASDAQ: ADVM) Halted, News Pending
... More